Funding Briefs

The Freestone, Calif.-based C.S. Fund (the initials stand for “charitable source”) rejected about 570 proposals last year in the process of selecting recipients of $1.5 million in grants. And, out of the kindness of its institutional heart, it has some advice to offer scientists who are thinking about submitting proposais for the coming year’s round of awards. First of all, says the foundation’s executive director, Marty Teitel, applicants should take the time to learn w

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Freestone, Calif.-based C.S. Fund (the initials stand for “charitable source”) rejected about 570 proposals last year in the process of selecting recipients of $1.5 million in grants. And, out of the kindness of its institutional heart, it has some advice to offer scientists who are thinking about submitting proposais for the coming year’s round of awards. First of all, says the foundation’s executive director, Marty Teitel, applicants should take the time to learn what projects—such as biological research with environmental implications—the organization tends to favor.

“We’ve written our guidelines brochure a thousand times to make it very clear. If more people would just read the brochure, they’d do better with their proposals,” says Teitel. Second, he strongly urges grant seekers to focus their proposals on the results their research is pursuing and the methods they intend to employ. “Usually grant seekers spend tremendous time describing the problem and not ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies